Progesterone receptor (PGR)
The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.
Overview
The progesterone receptor (PR, gene PGR) is a nuclear receptor whose expression is switched on by oestrogen signalling, so PR positivity in a breast cancer indicates an intact, functioning oestrogen receptor pathway and a better response to endocrine therapy; it is reported with ER and HER2 on every breast cancer pathology report. Progestins such as megestrol acetate and medroxyprogesterone act through the receptor and are used as hormonal treatment for advanced endometrial cancer and as later-line therapy in hormone receptor-positive breast cancer, and progestin-containing intrauterine systems are used for fertility-sparing treatment of early endometrial cancer.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.
- 1 · What it is
The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.
- 2 · What goes wrong in cancer
PGR encodes two isoforms, PR-A and PR-B, from alternative promoters; the receptor binds progesterone, dimerises and regulates transcription at progesterone response elements, and it cross-talks with the oestrogen receptor at shared chromatin sites.
- 3 · How drugs use it
No product in this corpus aims at Progesterone receptor (PGR) yet. Drugs cut off the hormone supply, block the receptor so the hormone cannot bind, or send the receptor to the cell's waste disposal.
External identifiers
Biology
PGR encodes two isoforms, PR-A and PR-B, from alternative promoters; the receptor binds progesterone, dimerises and regulates transcription at progesterone response elements, and it cross-talks with the oestrogen receptor at shared chromatin sites. In breast cancer PR expression is a marker of ER activity and of luminal A biology; loss of PR in an ER-positive tumour predicts a poorer response to endocrine therapy. In the endometrium progesterone opposes oestrogen-driven proliferation, which is why unopposed oestrogen causes endometrial cancer and progestins treat it.
- Breast epithelium and most ER-positive breast cancers
- Endometrium and endometrial cancers
- Ovary, uterus and brain
Latest papers
topQuery for this target: (TITLE:"Progesterone receptor" OR ABSTRACT:"Progesterone receptor" OR TITLE:"PGR" OR ABSTRACT:"PGR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Progesterone receptor (PGR), not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyFertility-sparing hormonal treatment of early endometrial cancer
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer.
- IdeaMolecular-class-directed adjuvant therapy in endometrial cancer
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer.
- TreatmentSerabelisib
Shares Endometrial cancer, HR-positive / HER2-negative breast cancer.
- TreatmentSapanisertib
Shares Endometrial cancer, HR-positive / HER2-negative breast cancer.
- TriallidERA
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- PersonMassimo Cristofanilli
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- PersonMitch Dowsett
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TreatmentRaloxifene
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.